Nick Pavlakis
Overview
Explore the profile of Nick Pavlakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
228
Citations
4830
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Janne P, Wang B, Cho B, Zhao J, Li J, Hochmair M, et al.
J Clin Oncol
. 2025 Jan;
:JCO2401269.
PMID: 39879577
Purpose: Mobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC). This open-label, phase III...
2.
Hanley M, Zhang S, Pavlakis N, Soo R, van der Wekken A, Ganju V, et al.
Clin Pharmacol Drug Dev
. 2025 Jan;
14(3):252-262.
PMID: 39815458
Mobocertinib is a kinase inhibitor designed to selectively target epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations in non-small cell lung cancer. This drug-drug interaction study assessed the...
3.
Gillson J, Byeon S, Chou A, Maloney S, Pavlakis N, Clarke S, et al.
Eur J Clin Invest
. 2024 Nov;
55(2):e14341.
PMID: 39487743
Background: Neoadjuvant chemotherapy (NAC) can provide improved survival outcomes in pancreatic ductal adenocarcinoma (PDAC) patients who respond to treatment, but currently available biomarkers cannot reliably predict NAC response. This study...
4.
Pavlakis N, Shitara K, Sjoquist K, Martin A, Jaworski A, Tebbutt N, et al.
J Clin Oncol
. 2024 Oct;
43(4):453-463.
PMID: 39365958
Purpose: Treatment options for refractory advanced gastric and esophagogastric junction cancer (AGOC) are limited. Regorafenib, an oral multikinase inhibitor, prolonged progression-free survival (PFS) versus placebo in the INTEGRATE I phase...
5.
Itchins M, Liang S, Brown C, Barnes T, Marx G, Chin V, et al.
JTO Clin Res Rep
. 2024 Sep;
5(9):100703.
PMID: 39309618
Introduction: ALK-positive lung cancers represent a molecularly diverse disease. With drug exposure, driving selection pressure, and resistance pathways, disease relapse will emerge. There is compelling rationale to investigate novel treatment...
6.
Jee J, Brannon A, Singh R, Derkach A, Fong C, Lee A, et al.
Nat Med
. 2024 Aug;
30(9):2499-2507.
PMID: 39147831
Cancer-associated venous thromboembolism (VTE) is a major source of oncologic cost, morbidity and mortality. Identifying high-risk patients for prophylactic anticoagulation is challenging and adds to clinician burden. Circulating tumor DNA...
7.
Coveler A, Reilley M, Zalupski M, Macarulla T, Fountzilas C, Ponz-Sarvise M, et al.
Clin Cancer Res
. 2024 Aug;
30(20):4609-4617.
PMID: 39106081
Purpose: Pancreatic ductal adenocarcinoma upregulates CD73, potentially contributing to immune surveillance evasion. Combining oleclumab (CD73 inhibitor) and durvalumab with chemotherapy may identify an effective treatment option. Patients And Methods: We...
8.
De Silva M, Chan D, Bernard E, Conner A, Mascall S, Bailey D, et al.
Pancreas
. 2024 Jul;
53(7):e560-e565.
PMID: 38986077
Objective: We investigated metabolic tumor volume (MTV) and total lesion glycolysis (TLG) on pre-treatment FDG-PET as prognostic markers for survival in patients with metastatic neuroendocrine neoplasms (NENs) receiving peptide receptor...
9.
Narayanan S, Yuile A, Venkatesh B, McKay M, Itchins M, Pavlakis N, et al.
Br J Clin Pharmacol
. 2024 May;
90(8):1942-1951.
PMID: 38706157
Aims: Therapeutic drug monitoring (TDM) has led to significant improvements in individualized medical care, although its implementation in oncology has been limited to date. Tyrosine kinase inhibitors (TKIs) are a...
10.
Fantoni A, Warburton L, Solomon B, Alexander M, Maddula M, Brown L, et al.
Clin Lung Cancer
. 2024 May;
25(5):449-459.
PMID: 38705835
Background: Seminal trials with first-line pembrolizumab for metastatic non-small cell lung cancer (NSCLC) mandated a maximum two-years treatment. We describe real-world outcomes of a multi-site Australian cohort of patients who...